- Page 5: haematologicaThe origin and power o
- Page 9 and 10: XVIII Congress of the Italian Socie
- Page 11 and 12: 2Educational Sessionssurgery. In av
- Page 13 and 14: 4Educational Sessionsclinical relev
- Page 15 and 16: 6Educational SessionsTREATMENT OF S
- Page 17 and 18: 8Educational Sessionssioners, aceno
- Page 19 and 20: 10Educational Sessionshaematologica
- Page 21 and 22: 12Selected Oral Communicationsleste
- Page 23 and 24: 14Selected Oral Communications11-84
- Page 25 and 26: 16Selected Oral Communicationssis,
- Page 27 and 28: 18Selected Oral CommunicationsSISET
- Page 29 and 30: 20Oral CommunicationsCO-002LYSOSOMA
- Page 31 and 32: 22Oral CommunicationsCO-006EXPRESSI
- Page 33 and 34: 24Oral Communicationsshowed that th
- Page 35 and 36: 26Oral CommunicationsCO-014ENOS GEN
- Page 37 and 38: 28Oral Communicationsstudy demonstr
- Page 39 and 40: 30Oral Communicationsmonths (2-39)
- Page 41 and 42: 32Oral Communicationscompared to he
- Page 43: 34Oral Communicationsoil) 2) a diet
- Page 47 and 48: 38Oral CommunicationsCO-038PRACTICE
- Page 49 and 50: 40Oral Communicationsjects; (ii) su
- Page 51 and 52: 42Oral Communicationsindependent ri
- Page 53 and 54: 44Oral Communicationsleast
- Page 55 and 56: 46Oral CommunicationsCO-051DESMOPRE
- Page 57 and 58:
48Oral Communicationssuring the pKa
- Page 59 and 60:
50Oral Communicationsthe Table, as%
- Page 61 and 62:
52Oral Communicationsels increased
- Page 63 and 64:
54Oral CommunicationsCO-066NITROPRA
- Page 65 and 66:
56Oral CommunicationsCO-070NORMAL F
- Page 67 and 68:
58Oral CommunicationsCO-074VENOUS T
- Page 69 and 70:
60Oral Communicationswith G20210A a
- Page 71 and 72:
62Oral CommunicationsCO-081CLOTTING
- Page 73 and 74:
64Oral Communications1. Decentraliz
- Page 75 and 76:
66Oral Communicationsspontaneous re
- Page 77 and 78:
68Oral Communicationsrecurrent DVT
- Page 79 and 80:
70Oral Communicationsdata strenghte
- Page 81 and 82:
72Oral Communicationscarrying the 5
- Page 83 and 84:
74Oral Communicationsmorphism, but
- Page 85 and 86:
76Oral CommunicationsCO-107HOMOCYST
- Page 87 and 88:
78Oral Communicationsmost frequent
- Page 89 and 90:
80Oral CommunicationsCO-115STUDY OF
- Page 91 and 92:
82Oral Communicationsinformed conse
- Page 93 and 94:
84Oral Communicationsnon-treated gr
- Page 95 and 96:
86Oral CommunicationsTF expression
- Page 97 and 98:
88Oral Communications@RISTOS, A PRO
- Page 99 and 100:
90Oral CommunicationsOral Communica
- Page 101 and 102:
92Oral CommunicationsCO-138EVALUATI
- Page 103 and 104:
94PostersU/dL respectively. Convers
- Page 105 and 106:
96Postersreport showing the presenc
- Page 107 and 108:
98PostersPO-008INTEGRIN α2β1 AND
- Page 109 and 110:
100Postersthe International Society
- Page 111 and 112:
102PostersPO-017GASTROINTESTINAL BL
- Page 113 and 114:
104PostersPO-021EVALUATION OF A NOV
- Page 115 and 116:
106PostersVWF-LIA appears to be at
- Page 117 and 118:
108PostersIn our hospital the routi
- Page 119 and 120:
110PostersPO-032GENETIC RISK FACTOR
- Page 121 and 122:
112PostersPO-036CATASTROPHIC VASCUL
- Page 123 and 124:
114Postersprostanoide intravenously
- Page 125 and 126:
116Posters5 mg folic acid daily, pl
- Page 127 and 128:
118Postersrelated to an acute infla
- Page 129 and 130:
120Postersexplanation of the increa
- Page 131 and 132:
122Postersgonadal hormone replaceme
- Page 133 and 134:
124Posters§Department of Nephrolog
- Page 135 and 136:
126PostersPostersWOMEN'S HEALTH ISS
- Page 137 and 138:
128Postersexcess of the anticoagula
- Page 139 and 140:
130PostersC (APC- Resistance). The
- Page 141 and 142:
132Postersgene substitution may be
- Page 143 and 144:
134Postersof LMWH or OA for the tre
- Page 145 and 146:
136Postersthe increased DVT risk as
- Page 147 and 148:
138Postersinternal jugular vein thr
- Page 149 and 150:
140PostersPostersANTIPLATELET THERA
- Page 151 and 152:
142PostersPO-093MONITORING PLATELET
- Page 153 and 154:
144PostersPostersACQUIRED COAGULATI
- Page 155 and 156:
146Postersshowed significantly high
- Page 157 and 158:
148PostersPO-105PROGNOSTIC SIGNIFIC
- Page 159 and 160:
150Postersscreen and SCT confirm we
- Page 161 and 162:
152PostersPO-114ECAPS STUDY: MULTIC
- Page 163 and 164:
154Postersnary Intensive Therapy Un
- Page 165 and 166:
156PostersPO-122GENOTYPE/PHENOTYPE
- Page 167 and 168:
158PostersPO-126MATERNAL-FETAL THRO
- Page 169 and 170:
160PostersPO-129RISK FACTOR FOR EXT
- Page 171 and 172:
162Postersfirst VTE episode were en
- Page 173 and 174:
164Postersative salvage and re-infu
- Page 175 and 176:
166PostersPO-141CYTOMEGALOVIRUS INF
- Page 177 and 178:
168PostersPO-145COMPLETE COMPRESSIO
- Page 179 and 180:
170PostersBackground: Acutely ill m
- Page 181 and 182:
172PostersPostersORAL ANTICOAGULANT
- Page 183 and 184:
174PostersPO-156DIAGNOSTIC EFFICACY
- Page 185 and 186:
176PostersPO-159ORAL ANTICOAGULATIO
- Page 187 and 188:
178PostersPO-163BLEEDING RISK IN PA
- Page 189 and 190:
180PostersHemorrhages represent the
- Page 191 and 192:
182Postersma and native whole blood
- Page 193 and 194:
184PostersPostersTHERAPY OF HEMOPHI
- Page 195 and 196:
186PostersPO-179INHIBITOR DEVELOPEM
- Page 197 and 198:
188PostersPO-183PROPOSAL OF IMMUNOT
- Page 199 and 200:
190PostersAt the last follow-up, 11
- Page 201 and 202:
192PostersPO-192SENSIBILITY OF THE
- Page 203 and 204:
Campagna F 11Campagnoli MF 137Campa
- Page 205 and 206:
Ieri M 142Iezzi A 11Ilari I 26, 167
- Page 207 and 208:
Rotilio D 32, 33Rotoli B 145Rotunno